A RARE CAUSE OF PITUITARY APOPLEXY: CABERGOLINE THERAPY

Aydin, B.; Aksu, O.; Asci, H.; Kayan, Mustafa; Korkmaz, H.

doi:10.4183/aeb.2018.113

A RARE CAUSE OF PITUITARY APOPLEXY: CABERGOLINE THERAPY

Aydin B., Aksu O., Asci H., Kayan M., Korkmaz H.

ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.14, sa.1, ss.113-116, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 1
Basım Tarihi: 2018
Doi Numarası: 10.4183/aeb.2018.113
Dergi Adı: ACTA ENDOCRINOLOGICA-BUCHAREST
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.113-116
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Pituitary apoplexy (PA) is a life-threatening clinical syndrome. Dopamine receptor agonists are the drugs of choice in the treatment of prolactinomas. The use of cabergoline is reported to cause an increased risk of PA, particularly in macroprolactinomas of cystic nature. In this report, we present a patient with a cystic macroprolactinoma who developed PA on the 16th week of cabergoline treatment.